FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47 | -53.5% | 22,348 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $101 | -25.7% | 21,303 | -11.0% | 0.00% | 0.0% |
| Q1 2023 | $136 | -42.9% | 23,947 | +1.5% | 0.00% | -50.0% |
| Q4 2022 | $238 | -100.0% | 23,583 | -6.8% | 0.00% | -50.0% |
| Q3 2022 | $567,000 | +87.1% | 25,293 | +107.1% | 0.00% | +100.0% |
| Q2 2022 | $303,000 | -50.4% | 12,214 | -22.6% | 0.00% | -33.3% |
| Q1 2022 | $611,000 | -29.0% | 15,771 | +7.3% | 0.00% | -25.0% |
| Q4 2021 | $860,000 | +21.8% | 14,696 | +23.4% | 0.00% | 0.0% |
| Q3 2021 | $706,000 | -8.8% | 11,913 | +33.6% | 0.00% | 0.0% |
| Q2 2021 | $774,000 | +24.2% | 8,918 | +18.1% | 0.00% | +33.3% |
| Q1 2021 | $623,000 | +11.6% | 7,552 | +23.0% | 0.00% | 0.0% |
| Q4 2020 | $558,000 | – | 6,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |